Charity calls on McDonald's to curb its use of antibiotics in animals

By Sumit Modi
Share

ShareAction, a charity movement which works to fight against the rise of drug-resistant bacteria and superbugs, has turned to McDonald’s, asking the fast food giant to stop the use of antibiotics in its animal supply chain.

The UK-based charity has launched a campaign asking the public to e-mail the company’s CEO, Steve Easterbrook, and express concerns about the issue.

ShareAction wants the company to cease its use of antibiotics in chickens, cows, and pigs unless absolutely necessary for disease treatment. Excessive use of the drugs can lead to bugs and infections becoming resistant to them, meaning that humans who consume affected meat lose resistance to the kind of superbugs which kill 23,000 Americans a year.

McDonald's recently made this change for poultry in its US restaurants, but the initiative needs to be expanded and made global, the charity has said.

ShareAction and the Farm Animal Investment Risk & Return initiative have attempted to push 10 big food companies – McDonald’s included – to announce a timeline for prohibiting antibiotics use. McDonald’s responded with a statement, claiming that such a thing was premature.

 

Follow @BizReviewUSA and @NellWalkerMG

Read the August issue of Business Review USA & Canada here

Share

Featured Articles

What is Nestlé CEO Laurent Freixe’s Action Plan?

Newly appointed CEO sets out action plan involving separating water brands into standalone business and boosting advertising and marketing spend

Will Mulberry Turn a New Leaf Under CEO Andrea Baldo?

International British luxury brand cuts quarter of head office staff as newly appointed CEO conducts strategic review

Female Board Members of Biggest UK Companies Paid 69% Less

Female board members of FTSE 100 companies are paid 69% less than male counterparts, as they find themselves frozen out of the biggest roles

Is This the Next CEO of LVMH?

Leadership & Strategy

How Burberry’s New CEO Is Going Back to Basics

Leadership & Strategy

Is Bayer CEO Bill Anderson Running Out of Time?

Leadership & Strategy